The Use of Glofitamab in Relapsed Diffuse Large B-Cell Lymphoma

H&O What is glofitamab, and how does it work for patients with relapsed and refractory (R/R) diffuse large B-cell lymphoma (DLBCL)? LF Glofitamab (Columvi, Genentech) is […]

Zandelisib and B-Cell Lymphomas

H&O How does zandelisib work? AZ Zandelisib is a phosphoinositide 3-kinase delta (PI3K-δ) inhibitor with a long half-life. PI3K comes in multiple isoforms, including alpha, beta, […]

Noncovalent BTK Inhibitors in B-Cell Lymphoma

H&O What are the limitations of standard (covalent) BTK inhibitors in B-cell malignancies? CC The 2 major limitations of covalent Bruton’s tyrosine kinase (BTK) inhibitors are […]

Loncastuximab Tesirine in Patients With B-Cell Non-Hodgkin Lymphoma

H&O What type of drug is loncastuximab tesirine? BK Loncastuximab tesirine is a novel antibody-drug conjugate. Antibody-drug conjugates consist of 3 components: a monoclonal antibody, […]

Advances in the Management of Primary Mediastinal Large B-Cell Lymphoma

H&O What is primary mediastinal large B-cell lymphoma? RA Primary mediastinal large B-cell lymphoma is a subtype of diffuse large B-cell lymphoma that is more […]

The Use of CAR T Cells in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

H&O Why are new treatments needed in DLBCL and MCL? PM Existing therapies are ineffective in a subset of patients or have toxicities that make […]

Aggressive B-Cell Lymphoma: The Double-Hit and Double-Expressor Phenotypes

H&O What are some recent developments in the understanding of genetics in aggressive B-cell lymphoma? SS There are between 60 and 80 different types of […]